GAMMA Investing LLC Buys 269 Shares of Masimo Co. (NASDAQ:MASI)

GAMMA Investing LLC boosted its position in Masimo Co. (NASDAQ:MASI) by 136.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 466 shares of the medical equipment provider’s stock after purchasing an additional 269 shares during the quarter. GAMMA Investing LLC’s holdings in Masimo were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. FMR LLC lifted its position in Masimo by 41.2% during the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after acquiring an additional 1,970,883 shares during the last quarter. State Street Corp lifted its holdings in shares of Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after purchasing an additional 10,179 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after purchasing an additional 262,370 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Masimo by 42.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after buying an additional 360,497 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Masimo by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after buying an additional 11,984 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MASI. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler boosted their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Finally, Wells Fargo & Company upped their target price on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $179.67.

Masimo Stock Down 1.4 %

MASI stock opened at $166.42 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm’s fifty day simple moving average is $168.12 and its 200-day simple moving average is $138.74. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $180.97. The company has a market capitalization of $8.91 billion, a P/E ratio of 114.77 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $0.63 EPS. As a group, equities research analysts forecast that Masimo Co. will post 4.03 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.